Claims for Patent: 3,950,529

Summary for Patent: 3,950,529

Title:	Amino acid formulations for patients with liver disease and method of using same
Abstract:	Amino acid formulations for administration to human patients with liver disease comprise mixtures of essential amino acids combined in novel relative proportions, and preferably also include non-essential amino acids. In particular, the combined molar proportions of isoleucine, leucine, and valine are from 40 to 300 times the molar proportion of tryptophan and from 15 to 135 times the molar proportion of phenylalanine, or phenylalanine and tyrosine. The formulations may be adapted for either intravenous or oral administration, but the preferred method of administration is by hyperalimentation infusion. The formulations and method can be utilized to provide nutritional support for liver diseased patients while reducing the incidence and severity of hepatic encephalopathy, and/or as primary therapy for treatment of hepatic encephalopathy.
Inventor(s):	Fischer; Josef E. (Boston, MA), Yoshimura; Norman N. (Woodland Hills, CA), Westman; Thomas L. (Northridge, CA), Deindoerfer; Fred H. (Northridge, CA)
Assignee:	Massachusetts General Hospital (Boston, MA) American Hospital Supply Corporation (Evanston, IL)
Application Number:	05/546,689
Patent Claims:	1. An amino acid formulation for administration to human patients with liver disease, comprising a mixture of the following essential and nonessential amino acids combined in proportions defined by the following interrelated molar ranges: wherein M represents the upper limit of the range for phenylalanine and is equal to 0.009 minus the respective molar amount of tyrosine present in said mixture, the combined molar amounts of phenylalanine and tyrosine being at least equal to 0.002 on the same respective molar basis, the respective molar proportions of isoleucine, leucine, valine, tryptophan, phenylalanine, and tyrosine being selected from the above molar ranges thereof so that the ratio of the combined molar proportions of isoleucine, leucine, and valine to (a) the molar proportion of tryptophan is within the numerical range from 40 to 300, and to (b) the combined molar proportion of phenylalanine and tyrosine is within the numerical range from 15 to 135. 2. The amino acid formulation of claim 1 in which said ratio with respect to (a) is from 50 to 90, and said ratio with respect to (b) is from 30 to 50. 3. The amino acid formulation of claim 1 in which said mixture of amino acids is dissolved in a sterile aqueous solution havng a total amino acid concentration of from 2 to 9 weight percent based on the solution. 4. The amino acid formulation of claim 3 in which said ratio with respect to (a) is from 50 to 90, and said ratio with respect to (b) is from 30 to 50. 5. The amino acid formulation of claim 1 prepared as an edible food for oral administration. 6. The method of supplying amino acids to a human patient having a diseased liver, comprising administering to said patient the amino acid formulation defined in claim 1. 7. The method of claim 6 in which said amino acid formulation is administered in an amount equivalent to at least 50 grams protein per patient per 24 hours. 8. The method of claim 7 in which said mixture of amino acids as defined in claim 1 is in the form of an aqueous solution of said amino acids and in which said solution is administered by intravenous infusion. 9. The method of claim 7 in which said mixture of amino acids as defined in claim 1 is administered by oral feeding. 10. An intravenous infusion solution of amino acids for administration to human patients with liver disease, consisting essentially of a sterile aqueous solution of the following essential and nonessential amino acids in the following moles per liter of solution concentrations: the respective concentrations of isoleucine, leucine, valine, tryptophan, and phenylalanine being selected from the above concentration ranges therefor so that the ratio of the total moles per liter of isoleucine, leucine, and valine to (a) the respective concentration of tryptophan is within the numerical range for said ratio of 50 to 90, and to (b) the respective concentration of phenylalanine is within the numberical range for said ratio of 30 to 50. 11. The method of supplying amino acids to a human patient having a diseased liver, comprising intravenously infusing said patient with the amino acid solution defined by claim 10. 12. The method of claim 11 in which said solution is infused in an amount equivalent to at least 50 grams protein per patient per 24 hours. 13. The intravenous infusion solution of claim 8 in which said ratio with respect to (a) is from 50 to 90, and said ratio with respect to (b) is from 30 to 50. 14. An amino acid preparation for oral administration to human patients with liver disease containing carbohydrate and/or fat nutrients together with a mixture of the following essential and nonessential amino acids combined in proportions defined by the following interrelated molar ranges: wherein M represents the upper limit of the range for phenylalanine and is equal to 0.009 minus the respective molar amount of tyrosine present in said mixture, the combined molar amounts of phenylalanine and tyrosine being at least equal to 0.002 on the same respective molar basis, the respective molar proportions of isoleucine, leucine, valine, tryptophan, phenylalanine, and tyrosine being selected from the above molar ranges thereof so that the ratio of the combined molar proportions of isoleucine, leucine, and valine to (a) the molar proportion of tryptophan is within the numerical range from 40 to 300, and to (b) the combined molar proportion of phenylalanine and tyrosine is within the numerical range from 15 to 135.